CAR T-cells for cancer therapy

References

• Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., ... Gottschalk, S. (2015). Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T-cells for the immunotherapy of HER2-positive sarcoma. Journal of Clinical Oncology, 33(15), 1688–1696.
   PubMed Web of Science ®Google Scholar
• Ahmed, N., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., ... Gottschalk, S. (2007). Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Research, 67(12), 5957–5964.
   PubMed Web of Science ®Google Scholar
• Altenschmidt, U., Kahl, R., Moritz, D., Schnierle, B. S., Gerstmayer, B., Wels, W., & Groner, B. (1996). Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clinical Cancer Research, 2(6), 1001–1008.
   PubMed Web of Science ®Google Scholar
• Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Juergens, H., Pule, M., & Rossig, C. (2009). 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunology, Immunotherapy, 58(12), 1991–2001.10.1007/s00262-009-0704-9
   PubMed Web of Science ®Google Scholar
• Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., ... June, C. H. (2014). Mesothelin-specific chimeric antigen receptor mRNA-engineered T-cells induce antitumor activity in solid malignancies. Cancer Immunology Research, 2(2), 112–120.
   PubMed Web of Science ®Google Scholar
• Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006). Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T-cells after allogeneic hematopoietic cell transplantation. Blood, 107(6), 2294–2302.
   PubMed Web of Science ®Google Scholar
• Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008). Adoptive transfer of effector CD8+T-cells derived from central memory cells establishes persistent T-cell memory in primates. Journal of Clinical Investigation, 118(1), 294–305.
   PubMed Web of Science ®Google Scholar
• Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016). Toxicity and management in CAR T-cell therapy. Molecular Therapy – Oncolytics, 3, 16011.
   PubMed Web of Science ®Google Scholar
• Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., ... Sadelain, M. (2013, March 20). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine, 5(177), 177ra738.
   Web of Science ®Google Scholar
• Brentjens, R. J., Riviere, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., ... Sadelain, M. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T-cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118(18), 4817–4828.
   PubMed Web of Science ®Google Scholar
• Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., ... Sadelain, M. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research, 13(18), 5426–5435.10.1158/1078-0432.CCR-07-0674
   PubMed Web of Science ®Google Scholar
• Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W. C., ... Jensen, M. C. (2015). Bioactivity and safety of IL13R alpha2-redirected chimeric antigen receptor CD8+ T-cells in patients with recurrent glioblastoma. Clinical Cancer Research, 21(18), 4062–4072.
   PubMed Web of Science ®Google Scholar
• Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., ... Coukos, G. (2008). Endothelin B receptor mediates the endothelial barrier to T-cell homing to tumors and disables immune therapy. Nature Medicine, 14(1), 28–36.
   PubMed Web of Science ®Google Scholar
• Buie, L. W., Pecoraro, J. J., Horvat, T. Z., & Daley, R. J. (2015). Blinatumomab: A first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Annals of Pharmacotherapy, 49(9), 1057–1067.
   PubMed Web of Science ®Google Scholar
• Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., ... Katz, S. C. (2015). Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunology, Immunotherapy, 64(7), 817–829.
   PubMed Web of Science ®Google Scholar
• Campana, D., Schwarz, H., & Imai, C. (2014). 4-1BB chimeric antigen receptors. The Cancer Journal, 20(2), 134–140.
   PubMed Web of Science ®Google Scholar
• Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., ... June, C. H. (2009). Control of large, established tumor xenografts with genetically retargeted human T-cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the USA, 106(9), 3360–3365.
   PubMed Web of Science ®Google Scholar
• Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., ... Kochenderfer, J. N. (2013). B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research, 19(8), 2048–2060.
   PubMed Web of Science ®Google Scholar
• Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., ... Dotti, G. (2015). Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nature Medicine, 21(5), 524–529.
   PubMed Web of Science ®Google Scholar
• Chang, Z. L., Silver, P. A., & Chen, Y. Y. (2015). Identification and selective expansion of functionally superior T-cells expressing chimeric antigen receptors. Journal of Translational Medicine, 13, 161.
   PubMed Web of Science ®Google Scholar
• Cheadle, E. J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R. E., & Gilham, D. E. (2014). CAR T-cells: Driving the road from the laboratory to the clinic. Immunological Reviews, 257(1), 91–106.
   PubMed Web of Science ®Google Scholar
• Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012). Local delivery of interleukin-12 using T-cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clinical Cancer Research, 18(6), 1672–1683.
   PubMed Web of Science ®Google Scholar
• Chmielewski, M. (2015). Abken H TRUCKs: The fourth generation of CARs. Expert Opinion on Biological Therapy, 15(8), 1145–1154.
   PubMed Web of Science ®Google Scholar
• Chmielewski, M., Rappl, G., Hombach, A. A., & Abken, H. (2012). T cells redirected by a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumor protection in the long term. Gene Therapy, 20, 177–186.
   PubMed Web of Science ®Google Scholar
• Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Jr., & Leahy, D. J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421(6924), 756–760.
   PubMed Web of Science ®Google Scholar
• Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., ... Gottschalk, S. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Molecular Therapy, 21, 629–637.
   PubMed Web of Science ®Google Scholar
• Chu, J., Deng, Y., Benson, D. M. J., He, S., Hughes, T., Zhang, J., ... Yu, J. (2013). CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 28(4), 917–927.
   PubMed Web of Science ®Google Scholar
• Ciceri, F., Bonini, C., Stanghellini, M. T., Bondanza, A., Traversari, C., Salomoni, M., ... Bordignon, C. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study. The Lancet Oncology, 10(5), 489–500.
   PubMed Web of Science ®Google Scholar
• Condomines, M., Arnason, J., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015). Tumor-targeted human T-cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition. PLoS One, 10(6), e0130518.
   PubMed Web of Science ®Google Scholar
• Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010). Enhanced tumor trafficking of GD2 chimeric antigen receptor T-cells by expression of the chemokine receptor CCR2b. Journal of Immunotherapy, 33(8), 780–788.
   PubMed Web of Science ®Google Scholar
• Croft, M. (2003). Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine & Growth Factor Reviews, 14(3–5), 265–273.
   PubMed Web of Science ®Google Scholar
• Cruz, C. R., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., ... Dotti, G. (2013). Infusion of donor-derived CD19 redirected virus-specific T-cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood, 122(17), 2965–2973.
   PubMed Web of Science ®Google Scholar
• Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., ... Brentjens, R. J. (2015). Enhancing antitumor efficacy of chimeric antigen receptor T-cells through constitutive CD40L expression. Molecular Therapy, 23(4), 769–778.
   PubMed Web of Science ®Google Scholar
• Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., ... Han, W. (2015). Tolerance and efficacy of autologous or donor derived T-cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology, 4(11), e1027469.
   PubMed Web of Science ®Google Scholar
• Davies, D. M., Foster, J., Van der Stegen, S. J., Parente-Pereira, A. C., Chiapero-Stanke, L., Delinassios, G. J., ... Maher, J. (2012). Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T-cells. Molecular Medicine, 18(4), 565–576.
   PubMed Web of Science ®Google Scholar
• Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., ... Brentjens, R. (2014). Efficacy and toxicity management of 19-28z CAR T-cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra25.
   PubMed Web of Science ®Google Scholar
• Davis, S., Gale, N. W., Aldrich, T. H., Maisonpierre, P. C., Lhotak, V., Pawson, T., ... Yancopoulos, G. D. (1994). Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science, 266(5186), 8169.
   Web of Science ®Google Scholar
• Depoil, D., Fleire, S., Treanor, B. L., Weber, M., Harwood, N. E., Marchbank, K. L., ... Batista, F. D. (2008). CD19 is essential for b cell activation by promoting B cell receptor-antigen micro cluster formation in response to membrane-bound ligand. Nature Immunology, 9, 63–72.
   PubMed Web of Science ®Google Scholar
• Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., ... Savoldo, B. (2009). T lymphocytes co-expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 113(25), 6392–6402.
   PubMed Web of Science ®Google Scholar
• Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., ... Brenner, M. K. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. The New England Journal of Medicine, 365(18), 1673–1683.
   PubMed Web of Science ®Google Scholar
• Doronin, I. I., Vishnyakova, P. A., Kholodenko, I. V., Ponomarev, E. D., Ryazantsev, D. Y., Molotkovskaya, I. M., & Kholodenko, R. V. (2014). Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer, 14, 295.
   PubMed Web of Science ®Google Scholar
• Dotti, G., Savoldo, B., Pule, M., Straathof, K. C., Biagi, E., Yvon, E., ... Rooney, C. M. (2005). Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood, 105(12), 4677–4684.
   PubMed Web of Science ®Google Scholar
• Dubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., ... Grauer, O. M. (2015). CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Journal of Neuro-Oncology, 18(6), 807–818.
   Web of Science ®Google Scholar
• Eaton, D., Gilham, D. E., O’Neill, A., & Hawkins, R. E. (2002). Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene therapy, 9(8), 527–535.
   PubMed Web of Science ®Google Scholar
• Eshhar, Z., Waks, T., Bendavid, A., & Schindler, D. G. (2001). Functional expression of chimeric receptor genes in human T-cells. The Journal of Immunological Methods, 248(1–2), 67–76.
   PubMed Web of Science ®Google Scholar
• Evans, A. G., Rothberg, P. G., Burack, W. R., Huntington, S. F., Porter, D. L., Friedberg, J. W., … Liesveld, J. L. (2015). Evolution to plasmablastic lymphoma evades cd19-directed chimeric antigen receptor T cells. British Journal of Haematology, 171, 205–209.
   PubMed Web of Science ®Google Scholar
• Faitschuk, E., Nagy, V., Hombach, A. A., & Abken, H. (2016). A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv. Gene Therapy, 23(10), 718–726.10.1038/gt.2016.48
   PubMed Web of Science ®Google Scholar
• Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016). Chimeric antigen receptor modified T-cells for the immunotherapy of patients with EGFR expressing advanced relapsed/refractory non-small cell lung cancer. Science China Life Sciences, 59(5), 468–479.
   PubMed Web of Science ®Google Scholar
• Finney, H.M., Akbar, A. N., & Lawson, A. D. (2004). Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain. The Journal of Immunology, 172(1), 104–113.10.4049/jimmunol.172.1.104
   PubMed Web of Science ®Google Scholar
• Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., ... Bollard, C. M. (2008). Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. Journal of Immunotherapy, 31, 500–505.
   PubMed Web of Science ®Google Scholar
• Fritsch, E. F., Hacohen, N., & Wu, C. J. (2014). Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology, 6(3), e29311.
   Web of Science ®Google Scholar
• Ganss, R., Ryschich, E., Klar, E., Arnold, B., & Hammerling, G. J. (2002). Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Research, 62(5), 1462–1470.
   PubMed Web of Science ®Google Scholar
• Garfall, A. L., Maus, M. V., Hwang, W. T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., ... Stadtmauer, E. A. (2015). Chimeric antigen receptor T-cells against CD19 for multiple myeloma. The New England Journal of Medicine, 373(11), 1040–1047.
   PubMed Web of Science ®Google Scholar
• Geiger, T. L., Nguyen, P., Leitenberg, D., & Flavell, R. A. (2001). Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood, 98(8), 2364–2371.
   PubMed Web of Science ®Google Scholar
• Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999). Expression of HER2/erbB-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology, 17(9), 2781–2788.
   PubMed Web of Science ®Google Scholar
• Grada, Z., Hegde, M., Byrd, T., Haffer, D. R., Ghazi, A., Brawley, V. S., ... Ahmed, N. (2013). TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy – Nucleic Acids, 2, e105.
   Google Scholar
• Gross, G., Waks, T., & Eshhar, Z. (1989). Expression of Immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the USA, 86(24), 10024–10028.
   PubMed Web of Science ®Google Scholar
• Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., ... June, C. H. (2013). Chimeric antigen receptor-modified T-cells for acute lymphoid leukemia. The New England Journal of Medicine, 368(16), 1509–1518.
   PubMed Web of Science ®Google Scholar
• Guo, B., Chen, M., Han, Q., Hui, F., Dai, H., Zhang, W., ... Han, W. (2016). CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. Journal of Cellular Immunotherapy, 2, 28–35.
   Google Scholar
• Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., ... Cavazzana-Calvo, M. (2003). LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., ... Cavazzana-Calvo, M. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation, 118(9), 3132–3142.
   PubMed Web of Science ®Google Scholar
• Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., ... Yu, J. (2015). CAR-engineered NK Cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Scientific Reports, 5, 11483.
   PubMed Web of Science ®Google Scholar
• Harris, D. T., & Kranz, D.M. (2015). Adoptive T cell therapies: A comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sc., 37(3), 220–230.
   PubMed Web of Science ®Google Scholar
• Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... Orentas, R. J. (2013). Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 121(7), 1165–1174.
   PubMed Web of Science ®Google Scholar
• Hassan, R., Bera, T., & Pastan, I. (2004). Mesothelin: A new target for immunotherapy. Clin Cancer Res., 10(12 Pt 1), 3937–3942.
   PubMed Web of Science ®Google Scholar
• Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., ... Ahmed, N. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Molecular Therapy, 21(11), 2087–2101.10.1038/mt.2013.185
   PubMed Web of Science ®Google Scholar
• Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., ... Ahmed, N. (2016). Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. Journal of Clinical Investigation, 126(8), 3036–3052.
   PubMed Web of Science ®Google Scholar
• Heimberger, A. B., Suki, D., Yang, D., Shi, W., & Aldape, K. (2005). The natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine, 3, 38.
   PubMed Web of Science ®Google Scholar
• Hinrichs, C. S., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z., ... Restifo, N. P. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8+ T-cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the USA, 106(41), 17469–17474.
   PubMed Web of Science ®Google Scholar
• Hombach, A., Hombach, A. A., & Abken, H. (2010). Adoptive immunotherapy with genetically engineered T-cells: Modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Therapy, 17(10), 1206–1213.10.1038/gt.2010.91
   PubMed Web of Science ®Google Scholar
• Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M., & Abken, H. (2012). OX40 co-stimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 (+) T-cells. Oncoimmunology, 1(4), 458–466.
   PubMed Web of Science ®Google Scholar
• Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., ... Dotti, G. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia, 24(6), 1160–1170.
   PubMed Web of Science ®Google Scholar
• Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., ... Riddell, S. R. (2010). The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood, 116(22), 4532–4541.
   PubMed Web of Science ®Google Scholar
• Hudziak, R. M., Schlessinger, J., & Ullrich, A. (1987). Increased expression of the putativegrowth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proceedings of the National Academy of Sciences of the USA, 84(20), 7159–7163.
   PubMed Web of Science ®Google Scholar
• Hynes, N. E., & MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 21(2), 177–184.
   PubMed Web of Science ®Google Scholar
• Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C. H., Geiger, T. L., & Campana, D. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18(4), 676–684.10.1038/sj.leu.2403302
   PubMed Web of Science ®Google Scholar
• Irving, B. A., & Weiss, A. (1991). The cytoplasmic domain of the T-cell receptor ζ chain is sufficient to couple to receptor associated signal transduction pathways. Cell, 64(5), 891–901.10.1016/0092-8674(91)90314-O
   PubMed Web of Science ®Google Scholar
• Jeha, S. (2001). Tumor lysis syndrome. Seminars in Hematology, 38(4 Suppl 10), 4–8.
   PubMed Web of Science ®Google Scholar
• Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T-cells in humans. Biology of Blood and Marrow Transplantation, 16(9), 1245–1256.
   PubMed Web of Science ®Google Scholar
• John, L. B., Kershaw, M. H., & Darcy, P. K. (2013). Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology, 2(10), e26286.
   PubMed Web of Science ®Google Scholar
• John, L. B., Devaud, C., Duong, C. P., Yong, C. S., Beavis, P. A., Haynes, N. M., ... Darcy, P. K. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T-cells. Clinical Cancer Research, 19(20), 5636–5646.
   PubMed Web of Science ®Google Scholar
• Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3(95), 95ra73.
   PubMed Web of Science ®Google Scholar
• Kalos, M., Frey, N. V., Grupp, S. A., Loren, A. W., Jemison, C., Gilmore, J., ... June, C. H. (2013). Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood, 122(21), 4162.
   PubMed Web of Science ®Google Scholar
• Katz, S. C., Burga, R. A., McCormack, E., Wang, L. J., Mooring, W., Point, G. R., ... Junghans, R. P. (2015). Phase I Hepatic Immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clinical Cancer Research, 21(14), 3149–3159.
   PubMed Web of Science ®Google Scholar
• Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., ... Hwu, P. (2006). A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clinical Cancer Research, 12(20 Pt 1), 6106–6115.
   PubMed Web of Science ®Google Scholar
• Kinch, M. S., & Carles-Kinch, K. (2003). Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clinical & Experimental Metastasis, 20(1), 59–68.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., & Rosenberg, S. A. (2011). Chimeric antigen receptor- modified T cells in CLL. The New England Journal of Medicine, 365, 1937–1938.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., ... Rosenberg, S. A. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T-cells genetically engineered to recognize CD19. Blood, 116(20), 4099–4102.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., ... Rosenberg, S. A. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T-cells. Blood, 119(12), 2709–2720.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., ... Rosenberg, S. A. (2013). Donor-derived CD19- targeted T-cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 122(25), 4129–4139.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P., Carpenter, R. O., Stetler-Stevenson, M., ... Rosenberg, S. A. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33(6), 540–549.
   PubMed Web of Science ®Google Scholar
• Kofler, D. M., Chmielewski, M., Rappl, G., Hombach, A., Riet, T., Schmidt, A., ... Abken, H. (2011). CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Molecular Therapy, 19(4), 760–767.10.1038/mt.2011.9
   PubMed Web of Science ®Google Scholar
• Kowolik, C., Topp, M., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., ... Cooper, L. J. (2006). CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research, 66(22), 10995–11004.10.1158/0008-5472.CAN-06-0160
   PubMed Web of Science ®Google Scholar
• Krug, C., Birkholz, K., Paulus, A., Schwenkert, M., Schmidt, P., Hoffmann, N., ... Schaft, N. (2015). Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. Cancer Immunology, Immunotherapy, 64, 1623–1635.
   PubMed Web of Science ®Google Scholar
• Lamers, C. H., Sleijfer, S., Vulto, A. G., Kruit, W. H., Kliffen, M., Debets, R., ... Oosterwijk, E. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. Journal of Clinical Oncology, 24(13), e20–e22.
   PubMedGoogle Scholar
• Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., ... Gratama, J. W. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood, 117(1), 72–82.10.1182/blood-2010-07-294520
   PubMed Web of Science ®Google Scholar
• Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., ... Gratama, J. W. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T-cells: Clinical evaluation and management of on-target toxicity. Molecular Therapy, 21(4), 904–912.
   PubMed Web of Science ®Google Scholar
• Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., ... Mackall, C. L. (2015). T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 385(9967), 517–528.
   PubMed Web of Science ®Google Scholar
• Li, Y. S., Hayakawa, K., & Hardy, R. R. (1993). The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. Journal of Experimental Medicine, 178(3), 951–960.
   PubMed Web of Science ®Google Scholar
• Li, Y. S., Wasserman, R., Hayakawa, K., & Hardy, R. R. (1996). Identification of the earliest B lineage stage in mouse bone marrow. Immunity, 5(6), 527–535.
   PubMed Web of Science ®Google Scholar
• Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., ... Zhao, Y. (2015). Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T-cells exhibit an increased therapeutic index against tumors in mice. Cancer Research, 75(17), 3596–3607.
   PubMed Web of Science ®Google Scholar
• Loskog, A., Giandomenico, V., Rossig, C., Pule, M., Dotti, G., & Brenner, M. K. (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia, 20(10), 1819–1828.10.1038/sj.leu.2404366
   PubMed Web of Science ®Google Scholar
• Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., ... Brenner, M. K. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T-cells in patients with neuroblastoma. Blood, 118(23), 6050–6056.
   PubMed Web of Science ®Google Scholar
• Luo, X., Xie, H., Long, X., Zhou, M., Xu, Z., Shi, B., Jiang, H., ... Li, Z. (2013). EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. PLoS One, 8(12), e83332.
   PubMed Web of Science ®Google Scholar
• Maher, J. (2014). Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Current Gene Therapy, 14(1), 35–43.
   PubMed Web of Science ®Google Scholar
• Mardiros, A., Forman, S. J., & Budde, L. E. (2015). T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Current Opinion in Hematology, 22(6), 484–488.
   PubMed Web of Science ®Google Scholar
• Marktel, S., Magnani, Z., Ciceri, F., Cazzaniga, S., Riddell, S. R., Traversari, C., ... Bonini, C. (2003). Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood, 101(4), 1290–1298.
   PubMed Web of Science ®Google Scholar
• Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., ... Grupp, S. A. (2014). Chimeric antigen receptor T-cells for sustained remissions in leukemia. The New England Journal of Medicine, 371(16), 1507–1517.
   PubMed Web of Science ®Google Scholar
• Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19- targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017–4023.
   PubMed Web of Science ®Google Scholar
• Maus, M. V. (2015). Designing CAR T cells for glioblastoma. Oncoimmunology, 4(12), e1048956.
   PubMed Web of Science ®Google Scholar
• Maus, M. V., & Levine, B. L. (2016). Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist, 21(5), 608–617.
   PubMed Web of Science ®Google Scholar
• Maus, M. V., Haa, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., ... June, C. H. (2013). T-cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research, 1, 26–31.
   PubMed Web of Science ®Google Scholar
• Mihara, K., Yanagihara, K., Takigahira, M., Imai, C., Kitanaka, A., Takihara, Y., ... Kimura, A. (2009). Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in b-cell non-hodgkin lymphoma. Journal of Immunotherapy, 32(7), 737–743.
   PubMed Web of Science ®Google Scholar
• Mihara, K., Yanagihara, K., Takigahira, M., Kitanaka, A., Imai, C., Bhattacharyya, J., ... Kimura, A. (2010). Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. British Journal of Haematology, 151(1), 37–46.
   PubMed Web of Science ®Google Scholar
• Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., ... June, C. H. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T-cells and increased anti-leukemic efficacy in vivo. Molecular Therapy, 17(8), 1453–1464.
   PubMed Web of Science ®Google Scholar
• Moon, E. K., Wang, L. C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., ... Albelda, S. M. (2014). Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors. Clinical Cancer Research, 20, 4262–4273.
   PubMed Web of Science ®Google Scholar
• Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., ... Rosenberg, S. A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126–129.10.1126/science.1129003
   PubMed Web of Science ®Google Scholar
• Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 18(4), 843–851.
   PubMed Web of Science ®Google Scholar
• Moritz, D., & Groner, B. (1995). A spacer region between the single chain antibody and the CD3 zeta-chain domain of chimeric T-cell receptor components is required for efficient ligand binding and signaling activity. Gene Therapy, 2(8), 539–546.
   PubMed Web of Science ®Google Scholar
• Muniappan, A., Banapour, B., Lebkowski, J., & Talib, S. (2000). Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Therapy, 7(1), 128–134.10.1038/sj.cgt.7700100
   PubMed Web of Science ®Google Scholar
• Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., ... Ramos, C. A. (2015). Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T-cells and is downregulated by lymphodepleting drugs. Blood, 125(25), 3905–3916.
   PubMed Web of Science ®Google Scholar
• Pameijer, C. R. J., Navanjo, A., Meechoovet, B., Wagner, J. R., Aguilar, B., Wright, C. L., ... Jensen, M. C. (2007). Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T-cell antigen receptor. Cancer Gene Therapy, 14(1), 91–97.10.1038/sj.cgt.7700993
   PubMed Web of Science ®Google Scholar
• Park, J. R., Digiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., ... Jensen, M. C. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy, 15(4), 825–833.
   PubMed Web of Science ®Google Scholar
• Park, H. J., Kusnadi, A., Lee, E. J., Kim, W. W., Cho, B. C., Lee, I. J., ... Ha, S. J. (2012). Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cellular Immunology, 278, 76–83.
   PubMed Web of Science ®Google Scholar
• Park, J. H., Riviere, I., Wang, X., Bernal, Y., Purdon, T., Halton, E., ... Brentjens, R. J. (2015). Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. Journal of Clinical Oncology, 33(15), 7010.
   Web of Science ®Google Scholar
• Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012). Tumor-targeted T-cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, 119(18), 4133–4141.
   PubMed Web of Science ®Google Scholar
• Pegram, H. J., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Giralt, S. A., Barker, J. N., & Brentjens, R. J. (2015). IL-12-secreting CD19-targeted cord blood-derived T-cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia, 29(2), 415–422.
   PubMed Web of Science ®Google Scholar
• Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., ... Pule, M. (2014). A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood, 124(8), 1277–1287.
   PubMed Web of Science ®Google Scholar
• Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., ... Smith, J. (2015). Multiplex genome-edited T-cell manufacturing platform for ‘off-the-shelf’ adoptive T-cell immunotherapies. Cancer Research, 75(18), 3853–3864.
   PubMed Web of Science ®Google Scholar
• Porter, D. L., Hwang, W. T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., ... June, C. H. (2015). Chimeric antigen receptor T-cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 7(303), 303ra139.
   PubMed Web of Science ®Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365(8), 725–733.
   PubMed Web of Science ®Google Scholar
• Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012). Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T-cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 51(3–4), 263–272.
   PubMed Web of Science ®Google Scholar
• Pule, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005). A chimeric T-cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T-cells. Molecular Therapy, 12(5), 933-941.
   PubMed Web of Science ®Google Scholar
• Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., ... Brenner, M. K. (2008). Virus-specific T-cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14(11), 1264–1270.
   PubMed Web of Science ®Google Scholar
• Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., ... Prince, H. M. (2013). Persistence and efficacy of second generation CAR T-cell against the LeY antigen in acute myeloid leukemia. Molecular Therapy, 21(11), 2122–2129.
   PubMed Web of Science ®Google Scholar
• Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016). Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 164, 770–779.
   PubMed Web of Science ®Google Scholar
• Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discovery, 3(4), 388–398.10.1158/2159-8290.CD-12-0548
   PubMed Web of Science ®Google Scholar
• Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., ... Bigner, D. D. (2010). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 31(28), 4722–4729.
   Web of Science ®Google Scholar
• Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., ... Goldenberg, D. M. (2005). Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clinical Cancer Research, 11(14), 5257–5264.
   PubMed Web of Science ®Google Scholar
• Sato, T., Neschadim, A., Konrad, M., Fowler, D. H., Lavie, A., & Medin, J. A. (2007). Engineered human tmpk/AZT As a novel enzyme/prodrug axis for suicide gene therapy. Molecular Therapy, 15(5), 962–970.10.1038/mt.sj.6300122
   PubMed Web of Science ®Google Scholar
• Savoldo, B., Rooney, C. M., Di Stasi, A., Abken, H., Hombach, A., Foster, A. E., ... Dotti, G. (2007). Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood, 110(7), 2620–2630.
   PubMed Web of Science ®Google Scholar
• Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., ... Dotti, G. (2011). CD28 co-stimulation improves expansion and persistence of chimeric antigen receptor-modified T-cells in lymphoma patients. Journal of Clinical Investigation, 121(5), 1822–1826.
   PubMed Web of Science ®Google Scholar
• Scheuermann, R. H., & Racila, E. (1995). CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia & Lymphoma, 18, 385–397.
   PubMed Web of Science ®Google Scholar
• Scholler, J., Brady, T. L., Binder-Scholl, G., Mitsuyasu, R. T., Bernstein, W. B., Aronson, N. E., ... June, C. H. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T-cells. Science Translational Medicine, 4(132), 132ra53.
   PubMed Web of Science ®Google Scholar
• Schuster, S. J., Svoboda, J., Nasta, S., Porter, D. L., Mato, A., Shah, G. D., ... June, C. H. (2015). Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Journal of Clinical Oncology, 33(15), 8516.
   Web of Science ®Google Scholar
• Serrano-Olvera, A., Duenas-Gonzalez, A., Gallardo-Rincon, D., Candelaria, M., & De la Garza-Salazar, J. (2006). Predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treatment Reviews, 32(3), 180–190.
   PubMed Web of Science ®Google Scholar
• Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K., Kakarla, S., Spencer, D. M., ... Gottschalk, S. (2011). T-cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood, 117(16), 4304–4314.
   PubMed Web of Science ®Google Scholar
• Shaffer, D. R., Zhou, P., & Gottschalk, S. (2014). Foreign or domestic CARs: Receptor ligands as antigen-binding domains. Medical Sciences, 2(1), 23–36.
   Google Scholar
• Sharifzadeh, Z., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Jamnani, F. R., & Moghimi, S. M. (2013). Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Letters, 334(2), 237–244.10.1016/j.canlet.2012.08.010
   PubMed Web of Science ®Google Scholar
• Shengnan, Y., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017). Chimeric antigen receptor T cells: A novel therapy for solid tumors. Journal of Hematology and Oncology, 10, 78.
   PubMed Web of Science ®Google Scholar
• Simons, F. E. (2009). Anaphylaxis: Recent advances in assessment and treatment. The Journal of Allergy and Clinical Immunology, 124(4), 625–636.
   PubMed Web of Science ®Google Scholar
• Singh, R., & Paterson, Y. (2007). Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Research, 67(5), 1887–1892.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., ... Ullrich, A. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707–712.
   PubMed Web of Science ®Google Scholar
• Song, D. G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012). CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood, 119(3), 696–706.10.1182/blood-2011-03-344275
   PubMed Web of Science ®Google Scholar
• Spear, P., Barber, A., Rynda-Apple, A., & Sentman, C. L. (2013). NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunology and Cell Biology, 91(6), 435–440.
   PubMed Web of Science ®Google Scholar
• Tey, S. K., Dotti, G., Rooney, C. M., Heslop, H. E., & Brenner, M. K. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T-cells after haploidentical stem cell transplantation. Biology of Blood and Marrow Transplantation, 13(8), 913–924.
   PubMed Web of Science ®Google Scholar
• Thomis, D. C., Marktel, S., Bonin, C., Traversari, C., Gilman, M., Bordignon, C., & Clackson, T. (2001). A Fas-based suicide switch in human T-cells for the treatment of graft-versus-host disease. Blood, 97(5), 1249–1257.
   PubMed Web of Science ®Google Scholar
• Thompson, S. K., Sullivan, T. R., Davies, R., & Ruszkiewicz, A. R. (2011). Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Annals of Surgical Oncology, 18(7), 2010–2017.
   PubMed Web of Science ®Google Scholar
• Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., ... Press, O. W. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T-cells. Blood, 112(6), 2261–2271.
   PubMed Web of Science ®Google Scholar
• Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., ... Press, O. W. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood, 119(17), 3940–3950.
   PubMed Web of Science ®Google Scholar
• Tintinalli, J. E. (2010). Emergency medicine: A comprehensive study guide (emergency medicine (Tintinalli)). New York, NY: McGraw-Hill Companies, pp. 177-182. ISBN 0-07-148480-9.
   Google Scholar
• Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O’Brien, S., Bargou, R. C., ... Kantarjian, H. M. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncology, 16(1), 57–66.
   PubMed Web of Science ®Google Scholar
• Torikai, H., Reik, A., Liu, P. Q., Zhou, Y., Zhang, L., Maiti, S., ... Cooper, L. J. (2012). A foundation for universal T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimeric antigen- receptor and eliminate expression of endogenous TCR. Blood, 119(24), 5697–5705.
   PubMed Web of Science ®Google Scholar
• Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., … Cooper, L. J. (2013). Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood, 122(8), 1341–1349.
   PubMed Web of Science ®Google Scholar
• Traversari, C., Marktel, S., Magnani, Z., Mangia, P., Russo, V., Ciceri, F., ... Bordignon, C. (2007). The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood, 109(11), 4708–4715.
   PubMed Web of Science ®Google Scholar
• Van der Stegen, S. J., Hamieh, M., & Sadelain, M. (2015). The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery, 14(7), 499–509.
   PubMed Web of Science ®Google Scholar
• Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., ... Dotti, G. (2006). T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 108(12), 3890–3897.
   PubMed Web of Science ®Google Scholar
• Wang, X., Chang, W. C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., ... Jensen, M. C. (2011). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablationof engineered cells. Blood, 118(5), 1255–1263.
   PubMed Web of Science ®Google Scholar
• Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., ... Press, O. W. (2007). Optimizing adoptive polyclonal T-cell immunotherapy of lymphomas, using a chimeric T-cell receptor possessing CD28 and CD137 costimulatory domains. Human Gene Therapy, 18(8), 712–725.
   PubMed Web of Science ®Google Scholar
• Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W. C., ... Jensen, M. C. (2012). Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T-cells manufactured at clinical scale. Journal of Immunotherapy, 35(9), 689–701.
   PubMed Web of Science ®Google Scholar
• Wang, J., Press, O. W., Lindgren, C. G., Greenberg, P., Riddell, S., Qian, X., ... Jensen, M. C. (2004). Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Molecular Therapy, 9(4), 577–586.
   PubMed Web of Science ®Google Scholar
• Wang, Q. S., Wang, Y., Lv, H. Y., Han, Q. W., Fan, H., Guo, B., ... Han, W. D. (2015). Treatment of CD33-directed chimeric antigen receptor-modified T-cells in one patient with relapsed and refractory acute myeloid leukemia. Molecular Therapy, 23(1), 184–191.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Zhang, W. Y., Han, Q. W., Liu, Y., Dai, H. R., Guo, Y. L., ... Wang, Q. S. (2014). Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T-cells. Journal of Clinical Immunology, 155(2), 160–175.
   Web of Science ®Google Scholar
• Weiss, A., & Littman, D. R. (1994). Signal transduction by lymphocyte antigen receptors. Cell, 76(2), 263–274.
   PubMed Web of Science ®Google Scholar
• Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., ... Maher, J. (2008). Retargeting of human T-cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor. Journal of Immunology, 180(7), 4901–4909.
   PubMed Web of Science ®Google Scholar
• Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T-cells through a small molecule–gated chimeric receptor. Science, 350(6258), aab4077.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137.
   PubMed Web of Science ®Google Scholar
• Zhang, J. G., Kruse, C. A., Driggers, L., Hoa, N., Wisoff, J., Allen, J. C., ... Jadus, M. R. (2008). Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. Journal of Neuro-Oncology, 88(1), 65–76.
   PubMed Web of Science ®Google Scholar
• Zhang, T., Wu, M. R., & Sentman, C. L. (2012). An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. The Journal of Immunology, 189(5), 2290–2299.10.4049/jimmunol.1103495
   PubMed Web of Science ®Google Scholar
• Zhao, Z., Condomines, M., van der Stegen, S. J., Perna, F., Kloss, C. C., Gunset, G., ... Sadelain, M. (2015). Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T-cells. Cancer Cell, 28(4), 415–428.
   PubMed Web of Science ®Google Scholar
• Zheng, Y., Zha, Y., & Gajewski, T. F. (2008). Molecular regulation of T-cell anergy. EMBO Reports, 9, 50–55.
   PubMed Web of Science ®Google Scholar
• Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3 kinase/AKT/Bcl-XL activation and CD8+ T-cell-mediated tumor eradication. Molecular Therapy, 18(2), 413–420.
   PubMed Web of Science ®Google Scholar
• Zhou, X., Di Stasi, A., Tey, S. K., Krance, R. A., Martinez, C., Leung, K. S., ... Dotti, G. (2014). Long-term outcome after haploidentical stem cell transplant and infusion of T-cells expressing the inducible caspase 9 safety transgene. Blood, 123(25), 3895–3905.
   PubMed Web of Science ®Google Scholar
• Zhou, G., & Levitsky, H. (2012). Towards curative cancer immunotherapy: Overcoming post therapy tumor escape. Clinical and Developmental Immunology, 2012, 124187.
   PubMedGoogle Scholar